Search Results - Paragodaarachchi, Aloka

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Nanocage-incorporated engineered destabilized 3'UTR ARE of ERBB2 inhibits tumor growth and liver and lung metastasis in EGFR T790M osimertinib- and trastuzumab-resistant and ERBB2-expressing NSCLC via the reduction of ERBB2

    Nanocage-incorporated engineered destabilized 3'UTR ARE of ERBB2 inhibits tumor growth and liver and lung metastasis in EGFR T790M osimertinib- and trastuzumab-resistant and ERBB2-... by Awah, Chidiebere U, Sun Mun, Joo, Paragodaarachchi, Aloka, Boylu, Baris, Nzegwu, Martin, Matsui, Hiroshi, Ogunwobi, Olorunseun

    Published in Frontiers in oncology
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  2. 2
    Magnetically Induced Brownian Motion of Iron Oxide Nanocages in Alternating Magnetic Fields and Their Application for Efficient siRNA Delivery

    Magnetically Induced Brownian Motion of Iron Oxide Nanocages in Alternating Magnetic Fields and Their Application for Efficient siRNA Delivery by Kang, Min A, Fang, Justin, Paragodaarachchi, Aloka, Kodama, Keita, Yakobashvili, Daniela, Ichiyanagi, Yuko, Matsui, Hiroshi

    Published in Nano letters
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Iron oxide and various metal oxide nanotubes engineered by one-pot double galvanic replacement based on reduction potential hierarchy of metal templates and ion precursors

    Iron oxide and various metal oxide nanotubes engineered by one-pot double galvanic replacement based on reduction potential hierarchy of metal templates and ion precursors by Paragodaarachchi, Aloka, Medvedovsky, Steven, Fang, Justin, Lau, Timothy, Matsui, Hiroshi

    Published in RSC advances
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    The Engineered Drug 3'UTRMYC1-18 Degrades the c-MYC-STAT5A/B-PD-L1 Complex In Vivo to Inhibit Metastatic Triple-Negative Breast Cancer

    The Engineered Drug 3'UTRMYC1-18 Degrades the c-MYC-STAT5A/B-PD-L1 Complex In Vivo to Inhibit Metastatic Triple-Negative Breast Cancer by Awah, Chidiebere U, Mun, Joo Sun, Paragodaarachchi, Aloka, Boylu, Baris, Ochu, Chika, Matsui, Hiroshi, Ogunwobi, Olorunseun O

    Published in Cancers
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    The Engineered Drug 3′UTRMYC1-18 Degrades the c-MYC-STAT5A/B-PD-L1 Complex In Vivo to Inhibit Metastatic Triple-Negative Breast Cancer

    The Engineered Drug 3′UTRMYC1-18 Degrades the c-MYC-STAT5A/B-PD-L1 Complex In Vivo to Inhibit Metastatic Triple-Negative Breast Cancer by Awah, Chidiebere U, Mun, Joo Sun, Paragodaarachchi, Aloka, Boylu, Baris, Ochu, Chika, Matsui, Hiroshi, Ogunwobi, Olorunseun O

    Published in Cancers
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:

Search Tools: